Diagnosis and treatment of the idiopathic inflammatory myopathies

Therapeutic Advances in Musculoskeletal Disease

Volumn 3, Issue 6, 2011, Pages 315-324

  Gazeley, David J ^a   Cronin, Mary E ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

dermatomyositis; idiopathic inflammatory myopathies; inclusion body myositis; polymyositis

Indexed keywords

ALEMTUZUMAB; AMINO ACID TRANSFER RNA LIGASE; AUTOANTIBODY; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DEXAMETHASONE; GLUCOCORTICOID; IMMUNOGLOBULIN; INFLIXIMAB; JO 1 ANTIBODY; METHOTREXATE; MUSCLE ENZYME; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; MYOSITIS SPECIFIC AUTOANTIBODY; PREDNISOLONE; PREDNISONE; RITUXIMAB; TACROLIMUS; UNCLASSIFIED DRUG;

ABNORMAL LABORATORY RESULT; ANTI SIGNAL RECOGNITION PARTICLE POSITIVE POLYMYOSITIS; ANTIBODY PRODUCTION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW TRANSPLANTATION; CANCER DIAGNOSIS; CANCER RISK; CLINICAL FEATURE; CORTICOSTEROID INDUCED MYOPATHY; DERMATOMYOSITIS; DIAGNOSTIC IMAGING; DIFFERENTIAL DIAGNOSIS; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG MEGADOSE; DRUG WITHDRAWAL; DYSPHAGIA; ELECTROMYOGRAPHY; FEVER; HEADACHE; HEART DISEASE; HISTOPATHOLOGY; HUMAN; IDIOPATHIC INFLAMMATORY MYOPATHY; INCLUSION BODY MYOSITIS; INFECTION; LOW DRUG DOSE; LUNG DISEASE; MALAISE; MUSCLE BIOPSY; MUSCLE DISEASE; MUSCLE STRENGTH; MUSCLE WEAKNESS; MUSCULAR DYSTROPHY; MUSCULOSKELETAL DISEASE; MYOSITIS; POLYMYOSITIS; PRIORITY JOURNAL; SKIN DISEASE; UNSPECIFIED SIDE EFFECT; WEIGHT REDUCTION;

EID: 84857485364     PISSN: 1759720X     EISSN: 17597218     Source Type: Journal    
DOI: 10.1177/1759720X11415306     Document Type: Article

References (48)

1. Alexanderson H. (2009) Exercise effects in patients with adult idiopathic inflammatory myopathies. Curr Opin Rheumatol 21: 158–163.
2. Amato A.A. Barohn R.J. (2009) Inclusion body myositis: old and new concepts. J Neurol Neurosurg Psychiat 80: 1186–1193.
3. Badrising U.A. Maat-Schieman M.L. Ferrari M.D. Zwinderman A.H. Wessels J.A.M. Bredveld F.C. et al. (2002) Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or placebo. Ann Neurol 51: 369–372.
4. Bazzani C. Cavazzana I. Ceribelli A. Vizzardi E. Dei Cas E. Franceschini F. (2010) Cardiological features in idiopathic inflammatory myopathies. J Cardiovasc Med 11: 906–911.
5. Bendewald M.J. Wetter D.A. Li X. Davis M.D. (2010) Incidence of dermatomyositis and clinically amyopathic dermatomyositis: a population- based study in Olmsted County, Minnesota. Arch Dermatol 146: 26–30.
6. Bohan A. Peter J.B. (1975) Polymyositis and dermatomyositis. Part I and II. N Engl J Med 292: 344–407.
7. Bunch T.W. (1981) Prednisone and azathioprine for polymyositis: long-term follow up. Arthritis Rheum 24: 45–48.
8. Callen J.P. (2010) Cutaneous manifestations of dermatomyositis and their management. Curr Rheumatol Rep 12: 192–297.
9. Chahin N. Engel A.G. (2008) Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBM. Neurology 70: 418–424.
10. Chahin N. Sorenson E. (2009) Serum creatine kinase levels in spinobulbar muscular atrophy and amyotrophic lateral sclerosis. Muscle Nerve 40: 126–129.
11. Chinoy H. Fertig N. Oddis C. Ollier W. Cooper R. (2007) The diagnostic utility of myositis autoantibody testing to predict the risk of cancer-associated myositis. Ann Rheum Dis 66: 1345–1349.
12. Christopher-Stine L. Casciola-Rosen L.A. Hong G. Chung T. Corse A.M. Mammen A.L. et al. (2010) A novel autoantibody recognizing 200-kd and 100 kd proteins is associated with an immune-mediated necrotizing myopathy. Arthritis Rheum 62: 2757–2766.
13. Cox S. Limaye V. Hill C. Blumbergs P. Roberts-Thomson P. (2010) Idiopathic inflammatory myopathies: diagnostic criteria, classification and epidemiological features. Int J Rheum Dis 10: 117–124.
14. Cronin M.E. Miller F.W. Hicks J.E. Dalakas M.C. Plotz P.H. (1989) The failure of intravenous cyclophosphamide therapy in refractory idiopathic inflammatory myopathy. J Rheumatol 16: 1225–1228.
15. Dalakas M. (1991) Polymyositis, dermatomyositis, and inclusion-body myositis. N Engl J Med 325: 1487–1496.
16. Dalakas M. Hohlfeld R. (2003) Polymyositis and dermatomyositis. Lancet 362: 971–982.
17. Dalakas M. Illa I. Dambrosia J.M. Soueidan S.A. Stein D.P. Otero C. et al. (1993) A controlled trial of high dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 329: 1993–2000.
18. Dalakas M. Rakocevic G. Schmidt J. Salajeghah M. McElroy B. Harris-Love M. et al. (2009) Effect of alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis. Brain 132: 1536–1544.
19. Dalakas M.C. (2010) Immunotherapy of myositis: issues, concerns and future prospects. Nat Rev Rheumatol 6: 129–137.
20. Dalakas M.C. Sonies B. Dambrosia J. Sekul E. Cupler E. Sivakumar E. et al. (1997) Treatment of inclusion-body myositis with IVIG: a double-blind, placebo-controlled study. Neurology 48: 712–716.
21. Dastmalchi M. Alexanderson H. Loell L. Stahlberg M. Borg K. Lundberg I.E. et al. (2007) Effect of physical training on the proportion of slow-twitch type I muscle fibers, a novel nonimmune-mediated mechanism for muscle impairment in polymyositis or dermatomyositis. Arthritis Rheum 57: 1303–1310.
22. Dastmalchi M. Grundtman C. Alexanderson H. Mavragani C.P. Einarsdottir H. Helmers S.B. et al. (2008) A high incidence of disease flares in open pilot study of infliximab in patients with refractory inflammatory myopathies. Ann Rheum Dis 67: 1670–1677.
23. Dion E. Cherin P. Payan C. Fournet J.C. Papo T. Maisonobe T. et al. (2002) Magnetic resonance imaging criteria for distinguishing between inclusion body myositis and polymyositis. J Rheumatol 29: 1897–1906.
24. Dourmishev L.A. Wollina U. (2006) Dermatomyositis: immunopathologic study of skin lesions. Acta Dermatovenerol Alp Panonica Adriat 15: 45–51.
25. Engel A. Franzini-Armstrong C. (2004) Myology, 3rd edn, McGraw-Hill: New York, pp. 1716–1719.
26. Gherardi R. Romain K. (2011) Pathogenic aspects of dermatomyositis, polymyositis and overlap myositis. Presse Med 40: e209–e218.
27. Henes J.C. Heinzelmann F. Wacker A. Seelig H.P. Klein R. Bornemann A. et al. (2009) Antisignal recognition particle-positive polymyositis successfully treated with myeloablative autologous stem cell transplantation. Ann Rheum Dis 68: 447–448.
28. Hill C.L. Zhang Y. Sigurgeirsson B. Pukkala E. Mellemkjaer L. Airio A. et al. (2001) Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet 357: 96–100.
29. Ji S.Y. Zeng F.Q. Guo Q. Tan H.F. Tang H.F. Luo Y.J. et al. (2010) Predictive factors and unfavourable prognostic factors of interstitial lung disease in patients with polymyositis or dermatomyositis: a retrospective study. Chin Med J 123: 517–522.
30. Kagen L.J. Aram S. (1987) Creatine kinase activity inhibitor in sera from patients with muscle disease. Arthritis Rheum 30: 213–217.
31. Klein R. Rosenbach M. Kim E.J. Kim B. Werth V.P. Dunham J. et al. (2010) Tumor necrosis factor inhibitor-associated dermatomyositis. Arch Dermatol 146: 780–784.
32. Kuo G.P. Carrino J.A. (2007) Skeletal imaging and inflammatory myopathies. Curr Opin Rheumatol 19: 530–535.
33. Levine T. (2005) Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum 52: 601–607.
34. Majithia V. Harisdangkul V. (2005) Mycophenolate mofetil (CellCept): an alternative therapy for autoimmune inflammatory myopathy. Rheumatology 44: 386–389.
35. Mastaglia F. Phillips B. (2002) Idiopathic inflammatory myopathies: epidemiology, classification, and diagnostic criteria. Rheum Dis Clin N Am 28: 723–741.
36. Ng K.P. Ramos F. Sultan M.F. Isenberg D.A. (2009) Concomitant diseases in a cohort of patients with idiopathic myositis during long-term follow-up. Clin Rheumatol 28: 947–953.
37. Oddis C.V. Scurba F.C. Abu Elmagd K. Starzl T.E. (1999) Tacrolimus in refractory polymyositis with interstitial lung disease. Lancet 353: 1762–1763.
38. Quartuccio L. de Marchi G. Scott C.A. Ferraccioli G. Beltrami C.A. de Vita S. et al. (2007) Treatment of inclusion body myositis with cyclosporine-A or tacrolimus: a successful long term management in patients with earlier active disease and concomitant autoimmune features. Clin Exp Rheumatol 25: 246–251.
39. Selva-O'Callaghan A. Fonollosa-Pla V. Trallero-Araguas E. Martinez-Gomez X. Simeon-Aznar C.P. Labrador-Horrillo M. et al. (2010 a) Nailfold capillary microscopy in adults with inflammatory myopathy. Sem Arthritis Rheum 39: 398–404.
40. Selva-O'Callaghan A. Grau J.M. Gamez-Cenzano C. Vidaller-Palacin A. Martinez-Gomez X. Trallero-Araguas E. et al. (2010 b) Conventional cancer screening versus PET/CT in dermatomyositis/polymyositis. Am J Med 123: 558–562.
41. Shamin E.A. Rider L.G. Miller F.W. (2000) Update on the genetics of the idiopathic inflammatory myopathies. Curr Opin Rheumatol 12: 482–491.
42. Sigurgeirsson B. Lindelof B. Edhag O. Allander E. (1992) Risk of cancer in patients with dermatomyositis or polymyositis–a population-based study. N Engl J Med 326: 363–367.
43. Targoff I.N. Miller F.W. Medsger T.A. Jr Oddis C.V. (1997) Classification criteria for the idiopathic inflammatory myopathies. Curr Opin Rheumatol 9: 527–535.
44. Valiyil R. Casciola-Rosen L. Hong G. Mammen A. Christopher-Stine L. (2010) Rituximab therapy for myopathy associated with anti-signal recognition particle antibodies: a case series. Arthritis Care Res 62: 1328–1334
45. van de Vlekkert J. Hoogendijk J.E. de Haan R.J. Algra A. van der Tweel L. van der Pol W.L. et al. (2010) Oral dexamethasone pulse therapy versus daily prednisolone in sub-acute onset myositis, a randomized clinical trial. Neuromusc Disord 20: 382–389.
46. Verschuuren J.J. (1997) Inclusion body myositis, In: Ed. Emery A. (ed.). Diagnostic Criteria for Neuromuscular Disorders, Royal Society of Medicine, European Neuromuscular Centre: Baarn, the Netherlands, pp. 81–84.
47. Walker U.A. (2008) Imaging tools for the clinical assessment of idiopathic inflammatory myositis. Curr Opin Rheumatol 20: 656–661.
48. Weber M.A. Krix M. Jappe U. Huttner H.B. Hartman M. Meyding-Lamade U. et al. (2006) Pathologic skeletal muscle perfusion in patients with myositis: detection with quantitative contrast-enhanced US–initial results. Radiology 238: 640–649.